Eli Lilly and Co. announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. As part of the agreement, Lilly will supply 388,000 doses of etesevimab to complement doses of bamlanivimab previously purchased by the U.S. government, with approximately 200,000 doses expected to ship 3Q21 and the remaining to be shipped in 4Q. This transaction is expected to generate approximately $330 million in revenue in...